Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CM 313

Next Previous
Drug Profile

CM 313

Alternative Names: CM-313

Latest Information Update: 04 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KeyMed Biosciences
  • Developer Institute of Hematology & Blood Diseases Hospital; KeyMed Biosciences
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Phagocyte stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic thrombocytopenic purpura
  • Phase I/II Systemic lupus erythematosus
  • Phase I Lymphoma; Multiple myeloma; Unspecified

Most Recent Events

  • 01 Apr 2025 Sichuan Provincial People's Hospital plans a clinical trial for Pemphigus (Combination therapy) in China (Parenteral) (NCT06904040)
  • 17 Feb 2025 Keymed Biosciences plans a phase II trial for IgA nephropathy (SC, Injection) in March 2025 (NCT06830395)
  • 04 Feb 2025 CM 313 is still in phase I trials for Multiple Myeloma (Combination therapy, Second-line therapy or greater, Monotherapy) and Lymphoma (Recurrent, Second-line therapy or greater) in China (KeyMed Biosciences pipeline, February 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top